Secukinumab Vs. Adalimumab for Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis at 52 Weeks from an Argentinian Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.771
https://www.valueinhealthjournal.com/article/S1098-3015(17)31105-1/fulltext
Title :
Secukinumab Vs. Adalimumab for Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis at 52 Weeks from an Argentinian Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31105-1&doi=10.1016/j.jval.2017.08.771
First page :
A535
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
736